Dare Bioscience Inc (DARE) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial ...

By Yahoo! Finance   |   1 month ago
Dare Bioscience Inc (DARE) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial ...

Sabrina Johnson, CEO, discusses Ovaprene's safety focus in the interim readout, with efficacy improving over time. The compounding strategy for Sildenafil Cream involves a 503B partner, and promotion emphasizes safety and education.

Read More

Did you find this insightful?